Karyopharm Therapeutics: signs a material agreement, says a debt obligation was accelerated and 2 other items
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001193125-26-388621
- Signs a material agreement (1.01)
- Says a debt obligation was accelerated (2.04)
- Sells unregistered shares (3.02)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Abvc Biopharma ABVC public float $37M, Jun 30, 2025
- BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
- Annovis Bio ANVS public float $36M, Jun 30, 2025
- Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025
- Grace Therapeutics GRCE public float $35M, Sep 30, 2025